



Gottlieb, S. L., Giersing, B. K., Hickling, J., Jones, R., Deal, C., Kaslow, D. C. (2017). Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017. *Vaccine*.  
<https://doi.org/10.1016/j.vaccine.2017.10.084>

Peer reviewed version

License (if available):  
CC BY-NC-ND

Link to published version (if available):  
[10.1016/j.vaccine.2017.10.084](https://doi.org/10.1016/j.vaccine.2017.10.084)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://www.sciencedirect.com/science/article/pii/S0264410X17314925> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

**Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017**

**Author names and affiliations:** Sami L. Gottlieb,<sup>a</sup> Birgitte K. Giersing,<sup>a</sup> Julian Hickling,<sup>b</sup> Rebecca Jones,<sup>b</sup> Carolyn Deal,<sup>c</sup> David C. Kaslow,<sup>d</sup> HSV Vaccine Expert Consultation Group\*

<sup>a</sup>World Health Organization (WHO), Geneva, Switzerland; <sup>b</sup>Working in Tandem Ltd, Cambridge, UK; <sup>c</sup>National Institutes of Allergy and Infectious Diseases, Bethesda, MD, USA; <sup>d</sup>PATH, Seattle, WA, USA

**Corresponding author:** Dr. Sami Gottlieb, Department of Reproductive Health and Research, WHO, Avenue Appia 20, CH-1211 Geneva 27, Switzerland; telephone: +41 22 791 34 24; email: [gottliebs@who.int](mailto:gottliebs@who.int)

\*HSV Vaccine Expert Consultation Group: Marie-Claude Boily (Imperial College, London, UK), Martha Brady (PATH, Washington, DC, USA), Nathalie Broutet (WHO, Geneva, Switzerland), Z. Mike Chirenje (University of Zimbabwe, Harare, Zimbabwe), Sinead Delany-Moretlwe (University of Witwatersrand, Johannesburg, South Africa), Christine Johnston (University of Washington, Seattle, WA, USA), David M. Koelle (University of Washington, Seattle, USA), Peter Leone (University of North Carolina, Chapel Hill, NC, USA), Odile Leroy (European Vaccine Initiative, UniversitätsKlinikum, Heidelberg, Germany), Katharine Looker (University of Bristol, Bristol, UK), Nicola Low (University of Bern, Bern, Switzerland), Purnima Madhivanan (Florida International University, Miami, FL, USA), Nelly Mugo (KEMRI, Nairobi, Kenya), Nicolas Nagot (University of Montpellier, Montpellier, France), Julie Schillinger (Centers for Disease Control and Prevention and New York City Department of Health and Mental Hygiene, New York, NY, USA), James Southern (Medicines Control Council, Pretoria, South Africa), Joao Paulo Toledo (Ministry of Health, Brasília, Brazil), Anna Wald (University of Washington, Seattle, WA, USA), Pingyu Zhou (Shanghai Skin Disease and STD Hospital, Shanghai, China).

## Abstract

The development of vaccines against herpes simplex virus (HSV) is an important global goal for sexual and reproductive health. A key priority to advance development of HSV vaccines is the definition of preferred product characteristics (PPCs), which provide strategic guidance on World Health Organization (WHO) preferences for new vaccines, specifically from a low- and middle-income country (LMIC) perspective. To start the PPC process for HSV vaccines, the WHO convened a global stakeholder consultation in March 2017, to define the priority public health needs that should be addressed by HSV vaccines and discuss the key considerations for HSV vaccine PPCs, particularly for LMICs. Meeting participants outlined an initial set of overarching public health goals for HSV vaccines in LMICs, which are: to reduce the acquisition of HIV associated with HSV-2 infection in high HIV-prevalence populations and to reduce the burden of HSV-associated disease, including mortality and morbidity due to neonatal herpes and impacts on sexual and reproductive health. Participants also considered the role of prophylactic versus therapeutic vaccines, the HSV types that should be targeted, important target populations, and infection and disease endpoints. This article summarizes the main discussions from the consultation.

*Keywords:* Herpes simplex virus; sexually transmitted infections; vaccines; HSV vaccines; preferred product characteristics

## 1 Introduction

Coinciding with the Decade of Vaccines and the Global Vaccine Action Plan, which calls for new research to expand the benefits of vaccination to all people, several global efforts have focused on the critical role of new innovations to improve sexual and reproductive health [1, 2]. In the 2016 Global Health Sector Strategy for Sexually Transmitted Infections (STIs), vaccine development was noted as a key innovation for future STI control [2]. The World Health Organization (WHO), the US National Institutes of Allergy and Infectious Diseases and global technical partners have outlined a comprehensive roadmap for development of effective new vaccines against STIs [3, 4]. The roadmap highlights the importance of focusing on herpes simplex virus (HSV) vaccine development because: (a) over half a billion people are estimated to have genital HSV infection globally [5, 6]; (b) HSV-2 is the leading cause of genital ulcer disease (GUD) worldwide; (c) HSV-2 fuels the HIV epidemic by increasing the risk of HIV acquisition and transmission [7]; (d) current HSV prevention measures have limited population impact [7]; and (e) product development of new candidate vaccines is more advanced for HSV than for other STIs, with the exception of human papillomavirus (HPV), for which approved vaccines already exist. In 2016, the need for HSV vaccines for global use was further highlighted by WHO's Product Development for Vaccines Advisory Committee [8].

Two priority activities have been identified by WHO to facilitate and accelerate the development of HSV vaccines for global use. The first is defining preferred product characteristics (PPCs), which provide strategic guidance on WHO's preferences for new vaccines, specifically from a low- and middle-income country (LMIC) perspective [9]. PPCs

are pathogen-, rather than product-specific, and summarize the preferences for parameters such as indications, target groups, immunization strategies, safety and efficacy, to address priority global public health and programmatic needs. The second activity is developing a value proposition (or investment case) for HSV vaccines that incorporate these PPCs, from a global public health perspective.

As a first step in defining PPCs for HSV vaccines, WHO convened a stakeholder consultation in March 2017 with HSV experts from academia, industry, and clinical medicine, as well as public health epidemiologists, regulators, and policymakers. The aims of this meeting were to: review data on HSV infection and disease, define the priority public health needs that should be addressed by an HSV vaccine, outline key considerations for establishing HSV vaccine PPCs, and assess how the current HSV vaccine pipeline aligns with public health need, especially for LMICs. This article summarizes the main discussions from the consultation.

## **2 HSV infection and disease**

Two closely related HSV types cause human infection and disease. HSV-2 is almost exclusively sexually transmitted and causes genital infection. It is the leading cause of GUD globally. HSV-1 is mainly transmitted by oral contact to cause oral-labial herpes, but can also be transmitted to the genital tract to cause genital herpes. During primary genital infection with either HSV-1 or HSV-2, patients can experience multiple genital ulcers, which can last for up to three weeks without antiviral therapy, alongside systemic symptoms such as fever, myalgia and headaches [7]. Primary infection can also be asymptomatic or unrecognized (subclinical) but still renders the individual infectious to partners. After replication in

epithelial cells of the genital tract, HSV travels up neurons to lumbo-sacral ganglia where it establishes latency. The immune response typically clears the mucosal infection, but not the latent virus in the ganglia. Over many years, viral reactivation is frequent, particularly for HSV-2, resulting in repeated replication and shedding of infectious virus at the genital-mucosal surface, with or without associated symptomatic recurrences of GUD. It had been thought that these reactivation episodes were rare, sporadic events; however, studies employing frequent genital swabbing [10] and modelling [11] suggest that HSV-2 infection is not a quiescent latent infection, but involves near-constant, low-grade release of virus from sensory neurons into the genital mucosa, where replication is controlled by local immune responses [11].

Up to 84% of shedding episodes are thought to be asymptomatic [12]. It has been estimated that transmission of HSV-2 is unlikely if the viral load during a shedding episode is less than  $10^4$  copies of HSV-2 DNA; however, much higher levels of HSV-2 shedding ( $10^6$  copies of HSV DNA) can be present even when lesions are very difficult to detect [13]. This is consistent with epidemiological observations that most HSV-2 transmission is due to asymptomatic shedding [14–16]. While estimates are based mainly on data from the USA, there has been a rigorous study of genital HSV-2 shedding conducted in Uganda that showed similar rates and quantities of total and subclinical shedding of virus [17]. However, whether transmission rates, particularly from asymptomatic shedding, are actually similar in LMICs and high-income countries (HICs) is not known. It is possible that transmission thresholds vary according to the presence of other genital infections, such as bacterial vaginosis, in

susceptible partners. In this regard, it has been shown that the quantity and frequency of HSV-2 shedding are increased in HIV co-infected people [18].

## **2.1 Epidemiology of HSV infection**

In 2012, an estimated 417 million people aged 15 to 49 years (range 274 to 678 million) worldwide were HSV-2-infected, equivalent to global prevalence of 11.3% [5]. Of these, 267 million (64%) were women, who have greater biological susceptibility to HSV-2 infection. Africa contributed most to the global total due to its large population and high HSV-2 infection prevalence (32%). South East Asia and the Western Pacific had lower prevalence (both 8%) but have large populations and, therefore, had high numbers of infected people (estimates of 74.6 million and 81.2 million, respectively). The global burden of HSV GUD has not been clearly elucidated, but assuming 10 to 20% of HSV-2 infected people have symptoms, and most recurrent GUD is related to HSV-2, an estimated 40 to 80 million people could have recurrent GUD worldwide [5].

By contrast, in 2012, the global prevalence of HSV-1 was 67% in 0 to 49 year olds (equivalent to 3.7 billion people), with most HSV-1 being acquired in childhood as an oral infection [6]. Acquisition of HSV-1 in childhood is however declining in several HICs such as the USA [19], so that increasing numbers of adolescents are susceptible to HSV-1 on initiation of sexual activity. Consequently, genital HSV-1 infection is now the leading cause of first episode genital herpes in some populations in HICs and is an important cause of genital herpes in the Americas, Europe and Western Pacific [6]. Overall, an estimated 140 million people have genital HSV-1 infection globally [6]. While the prevalence of genital HSV-1 infection is still thought to be relatively low in Africa and South East Asia [6], it is unknown whether the

proportion of individuals acquiring HSV-1 orally prior to adolescence may be starting to decrease in these regions as has been observed elsewhere [19], so that a growing number of people may first encounter HSV-1 via sexual contact. This is a gap in our understanding of HSV epidemiology globally.

## **2.2 Neonatal herpes**

Neonatal herpes is the most severe direct clinical consequence of HSV infection. It usually results from exposure to either HSV-1 or HSV-2 in the genital tract during delivery, although *in utero* and postnatal infections can occur. It is associated with high mortality, having an estimated case fatality rate of 60% without treatment. Morbidity is also high, often in the form of long-term neurological disabilities regardless of treatment [20]. Globally, an estimated 14,000 cases of neonatal herpes occurred annually during 2010 to 2015 (range 3,703 to 34,415 cases), equivalent to 10.3 cases per 100,000 births [20]. These estimates, however, rely heavily on data from studies in the USA, with only one study providing data on transmission risk [21]. The global estimates might under-estimate the number of cases in low resource settings, where Caesarean section rates can be lower and HIV prevalence higher than in HICs. There is a pressing need for primary data on the incidence of neonatal herpes in LMICs, especially in sub-Saharan Africa.

## **2.3 HSV-2 interactions with HIV**

Epidemiologic studies have identified a complex and synergistic relationship between HIV and HSV-2 infections [22], raising the possibility that an effective HSV vaccine could have an important impact on the acquisition and transmission of HIV.



A recent meta-analysis found that the risk of HIV acquisition is approximately tripled in the presence of prevalent HSV-2 infection, and five times higher for those with incident HSV-2 infection [23]. There are at least two possible mechanisms for this increased risk [24]: (a) breaks in the mucosa due to HSV-related ulcers that provide a more effective portal of entry for HIV [25]; and (b) HSV-2 infection and reactivation resulting in an infiltration into the genital mucosa of cells expressing receptors for HIV. Infiltration of CD4<sup>+</sup> T cells expressing CCR5 or CXCR4 and DC-SIGN<sup>+</sup> dendritic cells create a pool of target cells susceptible to HIV infection [26] (Figure 1). Increased densities of CD4<sup>+</sup> T cells have also been detected in foreskin samples from HSV-2 infected, HIV-uninfected men [27].

In an effort to reduce the excess risk of HIV among HSV-2-infected people, two clinical trials evaluated the impact of daily suppressive therapy with oral acyclovir, an antiviral drug that can reduce the frequency and duration of HSV symptoms, on HIV acquisition [28, 29]. Suppressive acyclovir therapy did not reduce the risk of HIV acquisition in these trials, even when GUD was reduced [29]. Investigators have since observed that acyclovir treatment, at current doses, is insufficient to suppress the enrichment of T cells and dendritic cells in the genital mucosa stimulated by HSV-2 infection, which often persist long after ulcer healing [26]. These findings support the importance of HSV-induced mucosal infiltration of HIV target cells as a mechanism for enhanced HIV risk.

HSV-2 infection is also implicated in an increased risk of HIV transmission. The presence of HSV-2-associated GUD has been estimated to increase the risk of HIV transmission approximately four-fold [30]. Higher HIV titres are found in genital secretions during HSV-2-reactivation episodes, and HSV-2 proteins might upregulate HIV replication, increasing HIV

viral load in plasma [22]. Several studies have shown that acyclovir and valacyclovir can decrease the frequency and quantity of genital HIV shedding and the plasma load of HIV [31], and a large double-blinded randomized clinical trial [31], found that acyclovir reduced the HIV plasma load, and the amount of HIV RNA in male and female genital fluids. A clinical trial in HIV-discordant couples, however, found that suppressive acyclovir had no effect on HIV transmission to the HIV negative partner, although GUD in the HIV-infected partner was reduced by 73% [32].

## **2.4 Other adverse outcomes**

Genital HSV infection can have important effects on sexual relationships and quality of life [33]. Genital herpes is often stigmatizing and the social consequences of the infection can have profound effects on sexual health and well-being, especially for adolescents and young adults.

Although most vaccine-development efforts to date have focused on HSV-2 infection, a future HSV vaccine might be effective against both HSV-1 and HSV-2. Orolabial herpes affects hundreds of millions of people, and can cause severe gingivostomatitis in childhood. HSV-1 can also result in less common outcomes such as HSV keratitis, an important cause of infectious corneal blindness globally, and HSV encephalitis, the leading cause of sporadic viral encephalitis.

## **2.5 Country perspectives**

Much of the data on epidemiology and burden of HSV disease have been collected from HICs, especially the USA. A broader global perspective is required to inform the WHO PPCs;

196 therefore, at the global stakeholder meeting, brief reports were presented on the nature  
197 and perception of HSV infection (including informal surveys and unpublished data) from  
198 Brazil, Burkina Faso, China, India, Kenya, South Africa and Zimbabwe.

199 Awareness and perceptions of HSV infection and disease and its impact on health varied  
200 between countries. Common themes in these LMICs included a relatively low awareness of  
201 the burden of HSV-2-related disease outcomes, even when several in-country studies had  
202 collected data on HSV-2 seroprevalence. In countries in sub-Saharan Africa, concerns about  
203 the increased risk of HIV infection associated with HSV-2 and the increased severity of HSV  
204 GUD among HIV-infected people were paramount. However, these concerns might change  
205 somewhat with increased roll-out of anti-retroviral therapy and newly available HIV  
206 prevention measures such as pre-exposure prophylaxis. Representatives from other  
207 settings, such as India, suggested that other maternal and sexual health outcomes such as  
208 neonatal herpes might be more important to policy makers. Country representatives were  
209 uncertain whether current data were sufficient to convince policy makers and purchasers in  
210 LMICs of the public health need for an HSV vaccine.

211 There has been little national policy-related activity regarding non-HIV STIs in many LMICs,  
212 although several have introduced HPV vaccines. HPV vaccines are, however, often promoted  
213 as anti-cancer rather than anti-STI vaccines, which can increase acceptability in adolescents  
214 and parents. Some discussion focused on the importance of an HSV vaccine to improve  
215 sexual and reproductive health generally. Many countries, including LMICs in Africa, are  
216 experiencing a youth bulge [34]; consequently, the need for, and potential impact of,

217 interventions targeting young people and those during their reproductive years in these  
218 countries could increase interest in HSV vaccines.

### 219 **3 Priority public health needs for HSV vaccines**

220 After reviewing the natural history and epidemiology of HSV infection and disease, meeting  
221 participants discussed the priority public health needs for HSV vaccines, particularly in  
222 LMICs. These discussions focused on the strategic goals of HSV vaccines, which can then  
223 guide more specific discussions on characteristics such as target populations, indications,  
224 clinical endpoints, safety and efficacy requirements, and vaccination strategies to meet  
225 these goals.

226 During the meeting, the group proposed the following primary public health goals for HSV  
227 vaccines in LMICs:

- 228 • to reduce the acquisition of HSV-2-associated HIV infection in high HIV-prevalence  
229 populations, and
- 230 • to reduce the burden of HSV-associated disease, including mortality and morbidity  
231 due to neonatal herpes, and impacts on sexual and reproductive health.

232 The group emphasized that the two goals listed above are in no particular order. The  
233 potential impact of HSV-2 vaccines on HIV infection could yield the most important  
234 reductions in morbidity and mortality and could strengthen the value proposition for  
235 investment in HSV vaccine development. However, because there are other existing and  
236 emerging tools for HIV prevention, such as broad delivery of anti-retroviral therapy and use  
237 of interventions such as pre-exposure prophylaxis, the role of HSV vaccines could become

238 less important to HIV prevention in the longer term. Furthermore, this goal only applies to  
239 areas of the world, such as sub-Saharan Africa, that have high prevalence of both HSV and  
240 HIV. Nonetheless, the meeting participants considered effective HSV vaccines to be an  
241 important strategy for HIV prevention, in addition to a range of other potential benefits.

242 In discussing the goal of reducing HSV-associated disease, meeting participants recognized  
243 that neonatal herpes is the most devastating direct consequence of genital HSV infection  
244 but thought to be rare, although the true incidence of this condition is not fully understood.  
245 The value proposition for HSV vaccines will need to balance these considerations, and the  
246 collection of primary data on neonatal herpes in LMICs will inform future discussions on the  
247 global public health need.

248 The burden of HSV-associated disease also includes overall effects on sexual and  
249 reproductive health, and several participants advocated for explicitly stating the benefits a  
250 vaccine would offer for sexual and reproductive health. It was emphasized that HSV  
251 infection has a range of potential adverse outcomes that, in sum, could drive the  
252 comprehensive impact of the vaccine beyond each individual disease outcome. The full  
253 range of effects on sexual and reproductive health – especially for young people – needs to  
254 be examined within the value proposition for HSV vaccines.

255 Meeting participants agreed that, in considering the greatest public health need, the priority  
256 should be on development of vaccines against HSV-2, because of its demonstrated role in  
257 propagating the HIV epidemic, and as the primary source of recurrent GUD and neonatal  
258 herpes in LMICs. However, an HSV vaccine that protects against both HSV-1 and HSV-2 could  
259 have farther-reaching benefits than one that only protects against HSV-2 and would be

particularly important in HIC settings, where genital HSV-1 is an increasing cause of first-episode genital herpes and an important cause of neonatal herpes [20]. More HSV-1 seroprevalence data from LMICs could help determine whether similar trends in HSV-1-related genital herpes and other outcomes will become important.

## **4 Development of vaccines against HSV**

There are two broad approaches to developing vaccines against HSV: prophylactic (preventive) vaccines, to prevent new infections, and therapeutic vaccines, to treat or modify existing infections. There are currently no licensed vaccines against HSV-1 or HSV-2, but encouragement is provided by the development of therapeutic vaccines and a prophylactic vaccine against varicella-zoster virus, another human  $\alpha$ -herpesvirus, closely related to HSV [35].

### **4.1 Prophylactic vaccines**

Prophylactic vaccines would be given before exposure to HSV, e.g., before first sexual contact (for prevention of HSV-2), or in infancy (for prevention of HSV-1). It is generally assumed that an effective prophylactic vaccine would act, at least in part, by inducing neutralizing antibodies against one or more of the 11 envelope proteins of HSVs. These include glycoprotein D (gD), which has been included in all candidate prophylactic HSV-2 vaccines tested clinically to date, and/or glycoprotein B (gB), which was a component in earlier HSV-2 vaccines [36, 37].

A few prophylactic vaccine candidates have been tested in clinical studies (Figure 2), the most advanced being a gD2-based vaccine with alum and monophosphoryl lipid A adjuvant

(GlaxoSmithKline, GSK). In a phase III trial, this vaccine showed 73% efficacy against GUD but only in a subset of participants: women who were seronegative for both HSV-1 and -2 when they entered the trial [38]. A second phase III trial (Herpevac), conducted only among women seronegative for HSV-1 and HSV-2, failed to show any protection against HSV-2 but did demonstrate 58% (95% CI, 12-80%) efficacy against HSV-1 GUD [39]. Efficacy against HSV-1 GUD appeared to correlate with anti-gD2 antibody titres [40]. The anti-HSV-1 activity may have been due to strong cross-reactivity between gD of HSV-1 and HSV-2, and greater susceptibility to neutralization for HSV-1 than HSV-2 [41].

## **4.2 Therapeutic vaccines**

Therapeutic vaccines against HSV-2 would be given to individuals with a known history of HSV-2 disease, with the aims of reducing disease severity and shedding of HSV-2 (both asymptomatic and during GUD recurrences), thereby reducing transmission of HSV-2.

Several different therapeutic vaccines have been, and are currently being, tested in phase I/II studies (Figure 2). An effective therapeutic vaccine is likely to act via cell-mediated immunity, possibly by stimulating resident memory T cells in the genital tract [42]. There is evidence that long-term resident CD8 $\alpha\alpha^+$  T cells at the dermis-epidermis junction in the skin of the genital tract might play a role in immune surveillance and containment of reactivation episodes [42]. If it is to control HSV release from sensory neurons and replication in mucosal epithelial cells, a therapeutic vaccine would need to induce a faster, more-effective immune response than that stimulated by reactivation episodes.

### **4.3 The HSV vaccine pipeline**

There are currently at least four HSV vaccines in clinical development, with at least one additional candidate likely to enter phase I studies in 2018, and all of the vaccines currently undergoing clinical testing are being evaluated as HSV-2 therapeutic vaccines. In addition, there are at least 20 candidates either in discovery or being researched by academic groups (Figure 2). Some of the candidates might also have potential as prophylactic vaccines because they include gD2 which has been a component of all prophylactic vaccines tested to date, although it should be noted that gD2 has not been shown to be an essential component for an HSV-2 prophylactic vaccine, nor does the inclusion of gD2 mean the vaccine will be effective. The key features of the HSV-2 vaccines currently in clinical trials are summarised in Table 1. None of these vaccines are being evaluated in LMIC populations.

HSV vaccines based on many other formats and platforms are being evaluated pre-clinically, including whole-virus (killed, live-attenuated or genetically disabled), monovalent or multivalent subunits with adjuvants, DNA, mRNA, live-virus vectors, peptides and nanoparticle-based [35].

### **4.4 Issues in the development of HSV vaccines**

Representative animal models do not currently exist for HSV infection or disease [35, 59], especially for the recurrent phase. For prophylactic vaccines, protection against intravaginal challenge in mice is often used; protection against the establishment of latency can also be tested in this model [56]. For both prophylactic and therapeutic vaccines, guinea pigs have been used because they experience a short period of recurrent genital disease after intravaginal HSV challenge [35]. Neither model has, however, been predictive of clinical



323 performance. Better animal models, possibly in non-human primates, could be used to  
324 screen candidates and de-risk vaccine development, particularly if the model exhibits  
325 recurrences following sexual transmission of the virus and/or long-term HSV shedding.

326 There are no known immunological correlates of protection for prophylactic or therapeutic  
327 HSV-2 vaccines [59]. Furthermore, prophylactic vaccines require very large trials; for  
328 example, the Herpevac trial in the USA enrolled 8,323 females who were seronegative for  
329 both HSV-1 and HSV-2 [39]. In addition, HSV-2 prevalence is decreasing in some areas of the  
330 USA, e.g., by as much as 50% in Seattle [60], so efficacy trials of prophylactic vaccines may  
331 have to be even larger in these settings. In areas with high HSV-2 incidence rates, such as  
332 sub-Saharan Africa, trials could be conducted with fewer participants [61], provided the  
333 vaccine would be made available to these areas once developed. Importantly, for  
334 prophylactic vaccines based on whole-virus platforms, a new diagnostic test may be  
335 required to distinguish infected individuals from vaccinated individuals.

336 In the past, GUD and/or infection (as measured by HSV-2 seroconversion) have been used as  
337 endpoints in phase III trials of prophylactic vaccines [38, 39]. From a technical standpoint,  
338 there is general consensus that it will be easier to achieve reduction in disease activity than  
339 to achieve complete immunity to infection [62]. Data from mouse models suggest that even  
340 if complete protection against infection is not achieved, vaccination can moderate the  
341 severity of primary infection and reduce the amount of virus establishing latency [56].  
342 Murine models can be used to differentiate between vaccines that protect against disease  
343 and those that are functionally sterilizing, i.e. prevent infection [56, 58], but with the  
344 limitation that it is unclear if performance in mice is predictive of efficacy in humans.

For therapeutic vaccines, the frequency of HSV-2 shedding has been used as a primary endpoint in early phase trials, along with reduction in lesion rate and duration of recurrence (Table 1; [47, 51]). As an endpoint, frequency of shedding has the advantages of being relatively consistent over time within an individual and correlating with, but having more statistical power than, both lesion rate and recurrence history. This allows for a one-way crossover study design in which participants can serve as their own controls. Thus, adequately powered therapeutic vaccine trials can be done with fewer participants, and more quickly than prophylactic vaccine trials, which can potentially de-risk these studies for industry. Phase I and II trials of therapeutic vaccines have typically enrolled up to a few hundred subjects.

## **5 Key considerations for HSV vaccine preferences for LMICs**

Given the priority public health needs discussed above, and the realities of HSV vaccine development and the vaccine pipeline, meeting participants discussed how to translate the strategic goals for HSV vaccines for LMICs into key considerations for HSV vaccine preferences. These discussions were intended to be the starting point for ongoing development of HSV vaccine PPCs.

### **5.1 Vaccine approaches**

There was consensus that both prophylactic and therapeutic vaccines could play roles in achieving the public health goals for HSV vaccines, and that the two vaccine approaches are sufficiently different that separate PPCs (or sections) should be developed for each.

Prophylactic vaccines would be the most appropriate for use in LMICs for the goal of preventing HSV-2-associated HIV acquisition, because any HSV-2 infection, regardless of symptoms of GUD, increases HIV risk. Nonetheless, both prophylactic and therapeutic HSV vaccines might reduce risk of HIV acquisition if they decreased or modified symptomatic and asymptomatic HSV infection in a way that reduces micro-ulcerations and HSV-induced inflammatory target cells for HIV. Prophylactic vaccines could use existing vaccine-delivery infrastructure, for example targeting adolescents receiving HPV vaccines, whereas therapeutic vaccines would need to be delivered to individual HSV-infected patients within the health-care system.

Several therapeutic HSV-2 vaccine candidates are in phase II trials in HICs, so a product might be available for implementation in LMICs sooner than for prophylactic vaccines. Therapeutic vaccines could be more attractive to vaccine developers (and investors) due to there being a sufficient market in HICs, and faster clinical development than for prophylactic vaccines. Therapeutic vaccines would, ideally, be at least as efficacious against GUD (and HSV transmission) as acyclovir. The effect of a therapeutic HSV vaccine on the increased risk of HIV acquisition among HSV-2-infected people remains unknown and could vary according to its immunologic mechanism and whether it may increase or decrease the presence of activated CD4<sup>+</sup> T cells in the genital tract, which are targets for HIV infection [24].

## **5.2. Target populations**

An HSV-2 prophylactic vaccine would most likely be offered to adolescents before first sexual exposure and immunity would need to last for at least the highest incidence period in young adulthood. Because many LMIC populations have high HSV-1 seroprevalence by

adolescence, HSV-2 prophylactic vaccines would need to be effective regardless of HSV-1 serostatus. If protection against both HSV types is required and/or achievable, then prophylactic HSV vaccines could be administered during infancy, for this strategy, it is possible that booster doses would be required later in life.

Therapeutic vaccines would most likely be offered to people with symptomatic GUD. To identify these people, they would need to seek care and be identified within an existing health care setting, such as primary care or family planning clinics. Implementation would be complex, as virologic assays for diagnosis of genital lesions may not be available and widely available serologic assays for HSV-2 infection are limited by poor specificity at the manufacturer recommended cut-offs [63]. Additional studies will be required to determine whether people with asymptomatic HSV infection, assuming they could be identified through serological screening, might also gain benefits from HSV vaccination. This might depend on whether the objectives are to reduce symptomatic HSV disease, reduce HIV acquisition, and/or prevent HSV or HIV transmission to sexual partners. Therapeutic vaccination of asymptomatic individuals would require the development of a diagnostic test (most likely blood-based) that is appropriate for use in LMICs.

## **5.2 Potential HSV-vaccine outcomes and endpoints**

One key issue is whether an HSV vaccine needs to prevent infection or disease. Prophylactic vaccines preventing HSV infection would be ideal because (a) even asymptomatic infection is associated with increased HIV acquisition [7, 26], and (b) many neonatal herpes cases are related to incident, rather than pre-existing, maternal infection [20, 21]. However, HSV vaccines that modify, but do not prevent infection might also have an impact on important

outcomes. Modelling studies presented at the meeting suggest that even imperfect HSV-2 vaccines (for preventing infection) could reduce HSV-2 incidence at the population level, especially when HSV-2 reactivation was reduced during breakthrough infection [64, 65]. Meeting participants emphasized that prophylactic vaccines do not need to induce an all-or-nothing “sterilizing” immune response, but rather an important objective is reducing the probability of infection for most people, and modifying the infection in the remainder so they have reduced reactivation-related disease. It remains unclear whether reducing the clinical intensity of primary genital HSV-2 infection through vaccination will lead to less frequent or severe symptoms or HSV-2 shedding after acquisition. Table 2 outlines some possible outcomes of HSV vaccination and considerations related to endpoints, which will be further reviewed during the PPC process.

### **5.3 Gaps in knowledge**

There are still gaps in knowledge that, if addressed, would greatly facilitate HSV vaccine development (Table 3). For several of the topics listed, there are data from HICs but the equivalent information is missing, or not recent, for LMICs.

## **6 Conclusions**

Defining PPCs for HSV vaccines is a key priority for advancing development of HSV vaccine candidates that will have global benefits and will be suitable for use in LMICs. The March 2017 WHO HSV vaccine global stakeholder consultation laid the groundwork for developing these PPCs, by defining priority public health needs that should be addressed by HSV vaccines and discussing key considerations for establishing HSV vaccine preferences for

430 LMICs. Meeting participants concluded that the global public health goals for HSV vaccines,  
431 in no particular order, should be reducing acquisition of HSV-associated HIV in high-  
432 prevalence populations and reducing the burden of HSV-associated disease, including  
433 mortality and morbidity due to neonatal herpes and impacts on sexual and reproductive  
434 health. The meeting attendees considered these goals to have similar priority, and sexual  
435 and reproductive health was highlighted as a framework around which multiple potential  
436 benefits of an HSV vaccine (e.g., preventing GUD and psychosocial sequelae) could be  
437 brought together. The group noted that the PPCs will need to be defined in parallel with  
438 generation of a public health value proposition for HSV vaccines, to attempt to quantify and  
439 weigh different aspects of the public health need with the potential costs and benefits of  
440 HSV vaccines in addressing that need.

441 In addition to HSV prophylactic vaccines, which would be ideal for LMIC use, the therapeutic  
442 HSV-2 vaccines that are the current focus of development efforts for HICs could also play an  
443 important role in addressing global public health need. Meeting participants agreed that  
444 PPCs should be defined for each. A working group, established by WHO, will now prepare  
445 draft PPCs, which will then be circulated for open comment from a larger group of  
446 stakeholders, before being finalized and communicated by WHO. The discussions from this  
447 consultation meeting, addressing considerations such as which HSV types should be  
448 targeted, vaccine indications, important target populations, infection and disease endpoints,  
449 critical efficacy and safety considerations, and pertinent vaccination strategies, will serve as  
450 the basis for defining and finalizing comprehensive PPCs for HSV vaccines.

451

## 452 Acknowledgements

453 We gratefully acknowledge participation of the following experts attending the WHO  
454 consultation for their contribution to the discussions: Marie-Claude Boily, Imperial College,  
455 London, UK; Martha Brady, PATH, Washington, DC, USA; Z. Mike Chirenje, University of  
456 Zimbabwe, Harare, Zimbabwe; Carolyn Deal (Co-Chair); NIAID, Bethesda, MD, USA; Sinead  
457 Delany-Moretlwe, University of Witwatersrand, Johannesburg, South Africa; Christine  
458 Johnston, University of Washington, Seattle, WA, USA; David C. Kaslow (Co-Chair), PATH,  
459 Seattle, WA, USA; David M. Koelle, University of Washington, Seattle, USA; Peter Leone,  
460 University of North Carolina, Chapel Hill, NC, USA; Odile Leroy, European Vaccine Initiative,  
461 UniversitätsKlinikum, Heidelberg, Germany; Katharine Looker, University of Bristol, Bristol,  
462 UK; Nicola Low, University of Bern, Bern, Switzerland; Purnima Madhivanan, Florida  
463 International University, Miami, FL, USA; Nelly Mugo, KEMRI, Nairobi, Kenya; Nicolas Nagot,  
464 University of Montpellier, Montpellier, France; Julie Schillinger, Centers for Disease Control  
465 and Prevention and New York City Department of Health and Mental Hygiene, New York,  
466 NY, USA; James Southern, Medicines Control Council, Pretoria, South Africa; Joao Paulo  
467 Toledo, Ministry of Health, Brasília, Brazil; Anna Wald, University of Washington, Seattle,  
468 WA, USA; Pingyu Zhou, Shanghai Skin Disease and STD Hospital, Shanghai, China.

469 Industry observers: Steve Bende, Sanofi Pasteur, Swiftwater, Pennsylvania (PA), USA; Philip  
470 Dormitzer, Pfizer, Pearl River, New Jersey (NJ), USA; Neil Finlayson (by telephone), Admedus  
471 Immunotherapies, Brisbane, Australia; Thomas Heineman, Genocoea, Cambridge,  
472 Massachusetts (MA), USA; Seth Hetherington, Genocoea, Cambridge, MA, USA; Mammen  
473 “Anza” P Mammen Jr, Vical, San Diego, CA, USA; Jan Henrick ter Meulen, Immune Design  
474 Corp., Seattle, WA, USA; Johann Mols, GSK, Rixensart, Belgium; Sanjay Phogat, Sanofi  
475 Pasteur, Swiftwater, PA, USA; Caroline Sagaert, GSK, Rixensart, Belgium.

476 WHO secretariat: Ian Askew, WHO Department of Reproductive Health and Research (RHR),  
477 Nathalie Broutet, WHO RHR; Birgitte K. Giersing, WHO Department of Immunizations,  
478 Vaccines, and Biologicals (IVB); Sami L. Gottlieb, WHO RHR; Julian Hickling (rapporteur),

479 Working in Tandem Ltd, Cambridge, UK; Raymond Hutubessy, WHO IVB; Rebecca Jones  
480 (rapporteur), Working in Tandem Ltd, Cambridge, UK.

481

482 Disclaimer: The views, findings, and conclusions contained within this report are those of  
483 the authors and do not represent the official positions or policies of WHO, NIAID, or CDC.

484

485 **Conflict of interest statement:** Drs. Gottlieb, Giersing, Hickling, Jones, Deal, Kaslow, Boily,  
486 Brady, Broutet, Chirenje, Delany-Moretlwe, Leroy, Looker, Low, Madhivanan, Nagot,  
487 Schillinger, Southern, Toledo, and Zhou report no conflicts of interest. Dr Johnston reports  
488 research funding to institution for clinical studies by Genocera Biosciences, Sanofi Pasteur,  
489 Agenus, and Vical Inc, and consultancy to Novavax; Dr Koelle reports research funding to  
490 institution for pre-clinical or clinical studies by Merck, Admedus, Sanofi Pasteur, and  
491 Immune Design Inc, consultancy with Biomedical Research Models, and consultancy with  
492 GSK that ended in 2016; Dr Leone reports research funding to institution for clinical studies  
493 by Genocera Biosciences and Vical Inc, and consultancy to Genocera Biosciences and Vical Inc  
494 on trial design; Dr Mugo reports research support to institution by Merck for HPV vaccine  
495 study; Dr Wald reports research funding to institution for clinical studies by Genocera  
496 Biosciences and Vical Inc, consultancies with Aicuris, Amgen, and GlaxoSmithKline, and  
497 travel reimbursement from Admedus.

498 **Funding:** The WHO HSV vaccine PPC expert consultation was supported by the National  
499 Institutes of Allergy and Infectious Diseases (U01 AI108543).



## References

1. WHO 2013. Global Vaccine Action Plan 2011 to 2020. Available at [http://www.who.int/immunization/global\\_vaccine\\_action\\_plan/en/](http://www.who.int/immunization/global_vaccine_action_plan/en/) Accessed 6 August 2017.
2. WHO 2016. Global health sector strategy on sexually transmitted infections 2016–2021. Towards ending STIs. Available at <http://apps.who.int/iris/bitstream/10665/246296/1/WHO-RHR-16.09-eng.pdf>. Accessed on 4 August 2017.
3. Broutet N, Fruth U, Deal C, Gottlieb SL, Rees H, participants of the 2013 STI Vaccine Technical Consultation. Vaccines against sexually transmitted infections: the way forward. *Vaccine* 2014;32:1630–7. doi:10.1016/j.vaccine.2014.01.053.
4. Gottlieb SL, Deal CD, Giersing B, Rees H, Bolan G, Johnston C, et al. The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps. *Vaccine* 2016;34:2939–47. doi:10.1016/j.vaccine.2016.03.111.
5. Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. *PLoS ONE* 2015;10:e114989. doi:10.1371/journal.pone.0114989.
6. Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. *PLoS ONE* 2015;10:e0140765. doi:10.1371/journal.pone.0140765.
7. Johnston C, Corey L. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. *Clin Microbiol Rev* 2016;29:149–61. doi:10.1128/CMR.00043-15.
8. Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V, WHO Product Development for Vaccines Advisory Committee. Report from the World Health Organization’s third Product

525 Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June  
526 2016. Vaccine 2017. doi:10.1016/j.vaccine.2016.10.090.

527 9. WHO 2017. WHO's preferred product characteristics (PPCs) and target product profiles  
528 (TPPs). Available at <http://www.who.int/immunization/research/ppc-tp/en/>. Accessed on  
529 4 August 2017.

530 10. Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang M-L, et al. Rapidly cleared episodes  
531 of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis  
532 2008;198:1141–9. doi:10.1086/591913.

533 11. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, et al. Frequent release of  
534 low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci  
535 Transl Med 2009;1:7ra16. doi:10.1126/scitranslmed.3000193.

536 12. Tronstein E, Johnston C, Huang M-L, Selke S, Magaret A, Warren T, et al. Genital  
537 shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-  
538 2 infection. JAMA 2011;305:1441–9. doi:10.1001/jama.2011.420.

539 13. Schiffer JT, Mayer BT, Fong Y, Swan DA, Wald A. Herpes simplex virus-2 transmission  
540 probability estimates based on quantity of viral shedding. J R Soc Interface  
541 2014;11:20140160. doi:10.1098/rsif.2014.0160.

542 14. Mertz GJ, Schmidt O, Jourden JL, Guinan ME, Remington ML, Fahnlander A, et al.  
543 Frequency of acquisition of first-episode genital infection with herpes simplex virus from  
544 symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33–9.

545 15. Mertz GJ, Coombs RW, Ashley R, Jourden J, Remington M, Winter C, et al. Transmission  
546 of genital herpes in couples with one symptomatic and one asymptomatic partner: a  
547 prospective study. J Infect Dis 1988;157:1169–77.

548 16. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual  
549 transmission of genital herpes. Ann Intern Med 1992;116:197–202.

550 17. Phipps W, Nakku-Joloba E, Krantz EM, Selke S, Huang M-L, Kambugu F, et al. Genital  
551 Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in  
552 Uganda. *J Infect Dis* 2016;213:439–47. doi:10.1093/infdis/jiv451.

553 18. Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, et al. Roles of  
554 clinical and subclinical reactivated herpes simplex virus type 2 infection and human  
555 immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma  
556 HIV-1 levels. *J Infect Dis* 2008;198:241–9. doi:10.1086/589621.

557 19. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex  
558 virus types 1 and 2--United States, 1999-2010. *J Infect Dis* 2014;209:325–33.  
559 doi:10.1093/infdis/jit458.

560 20. Looker KJ, Margaret AS, May MT, Turner KME, Vickerman P, Newman LM, et al. First  
561 estimates of the global and regional incidence of neonatal herpes infection. *Lancet Glob*  
562 *Health* 2017a;5:e300–9. doi:10.1016/S2214-109X(16)30362-X.

563 21. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and  
564 cesarean delivery on transmission rates of herpes simplex virus from mother to infant.  
565 *JAMA* 2003;289:203–9.

566 22. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus  
567 type-2 and HIV-1: new insights and interventions. *Curr HIV Res* 2012;10:228–37.

568 23. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, Boily M-C. Effect  
569 of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-  
570 analysis. *Lancet Infect Dis* 2017b;doi.org/10.1016/S1473-3099(17)30405-X.

571 24. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative  
572 mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. *AIDS*  
573 2007;21:589–98. doi:10.1097/QAD.0b013e328012b896.

574 25. Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency  
575 virus: double trouble. *Bull World Health Organ* 2004;82:447–53.

576 26. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1  
577 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1  
578 acquisition. *Nat Med* 2009;15:886–92. doi:10.1038/nm.2006.

579 27. Johnson KE, Redd AD, Quinn TC, Collinson-Streng AN, Cornish T, Kong X, et al. Effects of  
580 HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in  
581 adult foreskins from Rakai, Uganda. *J Infect Dis* 2011;203:602–9. doi:10.1093/infdis/jiq091.

582 28. Watson-Jones D, Weiss HA, Rusizoka M, Chagalucha J, Baisley K, Mugeye K, et al. Effect  
583 of herpes simplex suppression on incidence of HIV among women in Tanzania. *N Engl J Med*  
584 2008;358:1560–71. doi:10.1056/NEJMoa0800260.

585 29. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir  
586 on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex  
587 with men: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;371:2109–19.  
588 doi:10.1016/S0140-6736(08)60920-4.

589 30. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F,  
590 et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-  
591 discordant couples in Rakai, Uganda. *Lancet* 2001;357:1149–53. doi:10.1016/S0140-  
592 6736(00)04331-2.

593 31. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of  
594 aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized  
595 placebo-controlled trial in South Africa. *AIDS* 2009;23:461–9.  
596 doi:10.1097/QAD.0b013e32831db217.

597 32. Celum C, Wald A, Lingappa JR, Margaret AS, Wang RS, Mugo N, et al. Acyclovir and  
598 transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med*  
599 2010;362:427–39. doi:10.1056/NEJMoa0904849.

600 33. Fisman DN. Health related quality of life in genital herpes: a pilot comparison of  
601 measures. *Sex Transm Infect* 2005;81:267–70. doi:10.1136/sti.2004.011619.

602 34. Lin YF 2012. Youth Bulge: demographic dividend or demographic bomb in developing  
603 countries. World Bank Let's Talk Development blog. Available at  
604 [http://blogs.worldbank.org/developmenttalk/youth-bulge-a-demographic-dividend-or-a-](http://blogs.worldbank.org/developmenttalk/youth-bulge-a-demographic-dividend-or-a-demographic-bomb-in-developing-countries)  
605 [demographic-bomb-in-developing-countries](http://blogs.worldbank.org/developmenttalk/youth-bulge-a-demographic-dividend-or-a-demographic-bomb-in-developing-countries) Accessed 4 August 2017.

606 35. Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines  
607 for herpes simplex virus. *Vaccine* 2016;34:2948–52. doi:10.1016/j.vaccine.2015.12.076.

608 36. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, et al. Recombinant  
609 glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized  
610 controlled trials. Chiron HSV Vaccine Study Group. *JAMA* 1999;282:331–40.

611 37. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, et al.  
612 Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2  
613 glycoproteins D and B: results of a placebo-controlled vaccine trial. *J Infect Dis*  
614 1997;176:1129–34.

615 38. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al.  
616 Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med* 2002;347:1652–61.  
617 doi:10.1056/NEJMoa011915.

618 39. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy results  
619 of a trial of a herpes simplex vaccine. *N Engl J Med* 2012;366:34–43.  
620 doi:10.1056/NEJMoa1103151.

621 40. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, et al.  
622 Correlate of immune protection against HSV-1 genital disease in vaccinated women. *J Infect*  
623 *Dis* 2014;209:828–36. doi:10.1093/infdis/jit651.

624 41. Awasthi S, Belshe RB, Friedman HM. Better neutralization of herpes simplex virus 1  
625 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2  
626 subunit vaccine. *J Infect Dis* 2014;210:571–5. doi:10.1093/infdis/jiu177.

627 42. Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, Klock A, et al. Immune surveillance by  
628 CD8 $\alpha\alpha$ + skin-resident T cells in human herpes virus infection. *Nature* 2013;497:494–7.  
629 doi:10.1038/nature12110.

630 43. Dutton JL, Li B, Woo W-P, Marshak JO, Xu Y, Huang M, et al. A novel DNA vaccine  
631 technology conveying protection against a lethal herpes simplex viral challenge in mice.  
632 *PLoS ONE* 2013;8:e76407. doi:10.1371/journal.pone.0076407.

633 44. Dutton JL, Woo W-P, Chandra J, Xu Y, Li B, Finlayson N, et al. An escalating dose study to  
634 assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine,  
635 COR-1. *Hum Vaccin Immunother* 2016;0. doi:10.1080/21645515.2016.1221872.

636 45. Mo A, Musselli C, Chen H, Pappas J, Leclair K, Liu A, et al. A heat shock protein based  
637 polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective  
638 efficacy. *Vaccine* 2011;29:8530–41. doi:10.1016/j.vaccine.2011.07.011.

639 46. Wald A, Koelle DM, Fife K, Warren T, Leclair K, Chicz RM, et al. Safety and  
640 immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive  
641 persons. *Vaccine* 2011;29:8520–9. doi:10.1016/j.vaccine.2011.09.046.

642 47. Cohen JL. Vaccination to Reduce Reactivation of Herpes Simplex Virus 2. *J Infect Dis*  
643 2017. doi:10.1093/infdis/jix006.

644 48. Long D, Skoberne M, Gierahn TM, Larson S, Price JA, Clemens V, et al. Identification of  
645 novel virus-specific antigens by CD4<sup>+</sup> and CD8<sup>+</sup> T cells from asymptomatic HSV-2 seropositive  
646 and seronegative donors. *Virology* 2014;464–465:296–311. doi:10.1016/j.virol.2014.07.018.

647 49. Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, et al. An adjuvanted  
648 herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective  
649 therapeutic vaccine in Guinea pigs. *J Virol* 2013;87:3930–42. doi:10.1128/JVI.02745-12.

650 50. Flechtner JB, Long D, Larson S, Clemens V, Baccari A, Kien L, et al. Immune responses  
651 elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled

652 dose-ranging phase 1/2a trial. *Vaccine* 2016;34:5314–20.  
653 doi:10.1016/j.vaccine.2016.09.001.

654 51. Bernstein DI, Wald A, Warren T, Fife K, Tyring S, Lee P, et al. Therapeutic Vaccine for  
655 Genital Herpes Simplex Virus-2 Infection: Findings from a Randomized Trial. *J Infect Dis*  
656 2017. doi:10.1093/infdis/jix004.

657 52. Bernard M-C, Barban V, Pradezynski F, de Montfort A, Ryall R, Caillet C, et al.  
658 Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine  
659 candidate HSV529 in mice and guinea pigs. *PLoS ONE* 2015;10:e0121518.  
660 doi:10.1371/journal.pone.0121518.

661 53. Mundle ST, Hernandez H, Hamberger J, Catalan J, Zhou C, Stegalkina S, et al. High-purity  
662 preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo.  
663 *PLoS ONE* 2013;8:e57224. doi:10.1371/journal.pone.0057224.

664 54. Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, et al.  
665 Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines  
666 against herpes simplex virus type 2 in the mouse genital model. *PLoS ONE* 2012;7:e46714.  
667 doi:10.1371/journal.pone.0046714.

668 55. Muller WJ, Dong L, Vilalta A, Byrd B, Wilhelm KM, McClurkan CL, et al. Herpes simplex  
669 virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c  
670 mice after DNA immunization and infection. *J Gen Virol* 2009;90:1153–63.  
671 doi:10.1099/vir.0.008771-0.

672 56. Shlapobersky M, Marshak JO, Dong L, Huang M, Wei Q, Chu A, et al. Vaxfectin-  
673 adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine  
674 model of genital herpes infection. *J Gen Virol* 2012;93:1305–15. doi:10.1099/vir.0.040055-0.

675 57. Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. A Vaxfectin(®)-  
676 adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in

677 the guinea pig model of genital herpes. *Vaccine* 2012;30:7046–51.  
678 doi:10.1016/j.vaccine.2012.09.057.

679 58. Odegard JM, Flynn PA, Campbell DJ, Robbins SH, Dong L, Wang K, et al. A novel HSV-2  
680 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective  
681 immunity in mice and guinea pigs. *Vaccine* 2016;34:101–9.  
682 doi:10.1016/j.vaccine.2015.10.137.

683 59. Knipe DM, Corey L, Cohen JL, Deal CD. Summary and recommendations from a National  
684 Institute of Allergy and Infectious Diseases (NIAID) workshop on “Next Generation Herpes  
685 Simplex Virus Vaccines.” *Vaccine* 2014;32:1561–2. doi:10.1016/j.vaccine.2014.01.052.

686 60. Delany S, Gardella C, Saracino M, Magaret A, Wald A. Seroprevalence of herpes simplex  
687 virus type 1 and 2 among pregnant women, 1989-2010. *JAMA* 2014;312:746–8.  
688 doi:10.1001/jama.2014.4359.

689 61. Rajagopal S, Magaret A, Mugo N, Wald A. Incidence of herpes simplex virus type 2  
690 infections in Africa: a systematic review. *Open Forum Infect Dis* 2014;1:ofu043.  
691 doi:10.1093/ofid/ofu043.

692 62. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus  
693 vaccines. *Herpes* 2004;11 Suppl 3:161A–169A.

694 63. Mujugira A, Morrow RA, Celum C, Lingappa J, Delany-Moretlwe S, Fife KH, et al.  
695 Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes  
696 simplex virus type 2 antibodies in seven African countries. *Sex Transm Infect* 2011;87:238–  
697 41. doi:10.1136/sti.2010.047415.

698 64. Freeman EE, White RG, Bakker R, et al. Population-level effect of potential HSV2  
699 prophylactic vaccines on HIV incidence in sub-Saharan Africa. *Vaccine* 2009;27:940-6.

700 65. Gottlieb SL, Giersing B, Boily M-C, Chesson H, Looker KJ, Schiffer J, et al. Modelling  
701 efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings



702 from the World Health Organization Consultation on HSV Vaccine Impact Modelling. *Vaccine*  
703 2017; doi:10.1016/j.vaccine.2017.03.074.

704 66. Khan AA, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, et al. Phenotypic and  
705 functional characterization of herpes simplex virus glycoprotein B epitope-specific effector  
706 and memory CD8<sup>+</sup> T cells from symptomatic and asymptomatic individuals with ocular  
707 herpes. *J Virol* 2015;89:3776–92. doi:10.1128/JVI.03419-14.

708 67. Baccari A, Cooney M, Blevins TP, Morrison LA, Larson S, Skoberne M, et al. Development  
709 of a high-throughput  $\beta$ -Gal-based neutralization assay for quantitation of herpes simplex  
710 virus-neutralizing antibodies in human samples. *Vaccine* 2016;34:3901–6.  
711 doi:10.1016/j.vaccine.2016.05.033.

712 68. Newman RM, Lamers SL, Weiner B, Ray SC, Colgrove RC, Diaz F, et al. Genome  
713 Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus  
714 2. *J Virol* 2015;89:8219–32. doi:10.1128/JVI.01303-15.

715 69. Burrell S, Boutolleau D, Ryu D, Agut H, Merkel K, Leendertz FH, et al. Ancient  
716 Recombination Events between Human Herpes Simplex Viruses. *Mol Biol Evol*  
717 2017;34:1713–21. doi:10.1093/molbev/msx113.

718

719

720

721 **Table 1**722 *Summary of leading HSV vaccines in clinical and preclinical development, March 2017*

<b>Vaccine; developer</b>	<b>Composition</b>	<b>Type</b>	<b>Status</b>	<b>Data</b>
<b>COR-1; Admedus</b>	<b>DNA:</b> a mixture of two plasmids coding for full length gD2, and truncated gD2 with a ubiquitin tag; codon optimized.	Thera peutic	Phase II	<b>Preclinical:</b> [43]. <b>Phase I:</b> T-cell responses in 19 of 20 subjects; no increase in antibody response [44].
<b>HerpV; Agenus</b>	<b>Subunit plus adjuvant:</b> Thirty-two 35-mer peptides, complexed with human heat shock protein 70, plus QS-21 adjuvant.	Thera peutic	Not known	<b>Preclinical:</b> [45]. <b>Phase I:</b> Boosting of CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells [46]. <b>Phase II:</b> 15% reduction in shedding [47].
<b>GEN-003; Genocea</b>	<b>Subunit plus adjuvant:</b> truncated gD2 plus 39.2 kD fragment of ICP4 (infected cell protein 4) plus Matrix M2 adjuvant.	Thera peutic	Phase II	<b>Preclinical:</b> [48, 49]. <b>Phase I/IIa:</b> Boosting of T cells ( $\gamma$ -interferon producing) and antibodies [50]. Reduction in HSV-2 shedding (31 to 52%) and lesion rates immediately after dosing [51].
<b>HSV529; Sanofi Pasteur</b>	<b>Live, genetically disabled:</b> replication-defective HSV-2, with deletions of UL5 and UL29 genes.	Thera peutic	Phase I	<b>Preclinical:</b> [52–54]. <b>Phase I:</b> NCT01915212 and NCT02571166; data not available.
<b>VCL-HB01; Vical</b>	<b>DNA plus adjuvant.</b> DNA coding for HSV-2 UL46 (tegument protein VP11/12) and gD2, plus Vaxfectin® adjuvant.	Thera peutic	Phase II	<b>Preclinical:</b> [55–57]. <b>Phase I/II:</b> 49% reduction in lesion rate at 3 months and 57% reduction in lesion rate at 9 months in bivalent vaccine group; induction of $\gamma$ -

Vaccine; developer	Composition	Type	Status	Data
				interferon-producing T cells [47]
<b>G103;  Immune Design Corp</b>	<b>Subunit plus adjuvant:</b> trivalent gD, UL19 (truncated VP5, capsid) and UL25 (DNA packaging protein, structural); adjuvanted with proprietary glucopyranosyl lipid A in a stable emulsion (GLA-SE).	Thera peutic	Preclinical; phase I  scheduled for 2018.	<b>Preclinical:</b> [58].

723

724

Possible outcome of vaccination	Advantages, notes	Disadvantages, notes
<b>Prevention or reduction in HSV infection</b>	<p>To the extent that HSV infections can be prevented, all HSV-related sequelae (such as GUD, neonatal herpes, increased HIV risk) will be prevented. Thus, this will have the largest impact for individuals.</p> <p>To have an impact on HIV risk, prevention of infection might be needed, because HSV-2 increases HIV risk regardless of symptoms.</p> <p>Seroconversion can be used as an endpoint, especially if current assays are improved.</p>	<p>Prevention of infection will be more difficult to achieve than prevention of disease.</p> <p>Vaccine developers are likely to prefer a less difficult endpoint: for example, in the first phase III trial of a gD2 prophylactic vaccine, there was 73% efficacy against disease, but only 38% efficacy against infection in women who were seronegative for both HSV-1- and HSV-2 [38].</p>
<b>Prevention or reduction in GUD</b>	<p>A vaccine could prevent the most important symptoms of genital herpes even if infection is not completely prevented.</p> <p>Could be a potential outcome of both prophylactic and therapeutic vaccination.</p> <p>There is likely to be a strong market for preventing or reducing GUD in HICs, which could help advance vaccine development for LMICs.</p>	<p>It is not yet known if the societal cost of GUD alone is sufficient to justify HSV vaccine development and purchase for LMICs.</p> <p>The burden of HSV-related GUD and its effect on quality of life is unknown in many LMICs.</p>

Possible outcome of vaccination	Advantages, notes	Disadvantages, notes
<b>Reduction in HSV shedding</b>	<p>A vaccine could reduce HSV shedding and risk of transmission even if infection is not completely prevented.</p> <p>This could be a potential outcome of both prophylactic and therapeutic vaccination.</p> <p>Reduction in HSV shedding is relatively easy to measure and is likely to be a marker for disease activity and potential transmission to partners or neonates.</p>	<p>The transmission threshold of HSV in humans is not known, and it is not clear how this data could be obtained.</p> <p>Assays could be developed that detect low levels of infection, sufficient to induce seroconversion but low enough that transmission doesn't occur, or rarely (Table 3).</p>
<b>Reduction in HSV transmission</b>	<p>A vaccine could reduce HSV transmission even if infection is not completely prevented.</p> <p>Modeling suggests that even an imperfect HSV vaccine could reduce HSV incidence in a population [64].</p> <p>Reduction in HSV transmission risk to a sexual partner may be a desirable characteristic for patients (for example for therapeutic vaccines in HICs)</p>	<p>Direct measurement of HSV transmission following vaccination would be difficult, though not impossible, for example via discordant couple studies.</p> <p>The transmission threshold of HSV in humans is not known, and it is not clear how these data could be obtained.</p>
<b>Reduction in HIV acquisition or transmission risk</b>	<p>Reduction in HSV-related HIV infection could have a significant public health benefit, and would strengthen the public health investment case for HSV vaccines in LMICs.</p>	<p>It might be difficult to measure impacts on HIV acquisition and transmission in clinical trials (though not impossible) and, therefore, be difficult to include as a primary indication for</p>

Possible outcome of vaccination	Advantages, notes	Disadvantages, notes
	Modelling suggests that even an imperfect HSV vaccine could reduce HIV incidence in a population [64].	<p>vaccination.</p> <p>Interest in effects on HIV compared with those on other outcomes will vary between countries, depending on HIV prevalence.</p> <p>Consideration will need to be given to the marginal benefit HSV vaccination could have on HIV given improved access to anti-retroviral therapy and new HIV prevention measures.</p> <p>Acyclovir has been shown to reduce GUD but without having an effect on HIV acquisition. A therapeutic vaccine would need to perform better than antivirals.</p> <p>The effect of therapeutic vaccines on modifying HIV risk requires evaluation.</p>
<b>Prevention or reduction in neonatal herpes</b>	Neonatal herpes is the most severe direct outcome of HSV infection and its prevention could strengthen the public health value proposition for HSV vaccine development.	<p>Neonatal herpes is rare and so it will be difficult to measure as an outcome in clinical trials.</p> <p>The health and societal costs of neonatal herpes needs to be better quantified globally, balancing severe morbidity and mortality with its rare occurrence.</p>
<b>Improved sexual and</b>	Improved sexual and reproductive health is	Quality of sexual and reproductive health is

Possible outcome of vaccination	Advantages, notes	Disadvantages, notes
reproductive health	<p>considered by some to be an important rationale for HSV vaccines, incorporating the totality of benefits of the vaccine.</p> <p>Data should be collected on the impact of HSV vaccines on exploratory endpoints such as relationships and quality of life.</p>	<p>difficult to quantify.</p> <p>Existing quality of life scales for genital HSV need to be used to determine health utilities for HSV infection.</p>

727

	<b>Gap</b>	<b>Notes</b>
<b>Clinical</b>	What is the level of HSV shedding (infectious dose) below which transmission of HSV-1 and HSV-2 does not occur?	<p>Knowing this threshold would allow for smaller clinical trials with virus shedding as a primary endpoint. It will, however, be very difficult to design human studies to define the infectious dose.</p> <p>This could also be important for genital HSV-1 infections, where there are fewer symptomatic reactivations.</p>
	What are the asymptomatic transmission rates of HSV-1 and HSV-2 in LMICs? Can we assume they are the same as in HICs, and that they are responsible for most transmissions?	It is possible that the transmission threshold(s) are different in LMICs compared with HICs due to differences in presence of other reproductive tract infections.
	<p>What is the burden of HSV-related GUD in LMICs?</p> <p>Is GUD regarded as a public health problem?</p> <p>What are the consequences of HSV-2 on the quality of life, including parameters such as mental health, productivity, and relationships?</p>	<p>More epidemiological data need to be collected, using standardized protocols, to quantify the impact of HSV-associated disease in LMICs, and to develop a public health value proposition for HSV vaccines to present to stakeholders.</p>
	What is the burden of neonatal herpes in LMICs?	There are very limited data from LMICs. Current estimates depend on data from studies in the USA




	Gap	Notes
		only [20].
	How might a therapeutic vaccine affect the risk of HIV acquisition if it stimulates increased numbers of CD4 <sup>+</sup> T cells and dendritic cells in the genital mucosa? Can the potential risk be quantified in advance of clinical studies?	It might be difficult to design studies to predict this risk, but this is an important question. The rate of HIV acquisition could be measured in large clinical trials in high-risk populations.
	What are the best settings and populations for trials of prophylactic vaccines?	Discordant couples might not be representative of the general population, and some HICs now have a low incidence of HSV-2 in some populations who usually volunteer for vaccine studies. Are there settings relevant to LMICs with sufficiently high HSV-2 incidence that could be used?
<b>Virology and immunology</b>	What are the correlates of protection from infection, disease and shedding, for prophylactic and therapeutic vaccines?	<p>Correlates of protection, especially for cell-mediated immunity, are largely unknown for both HSV-1 and HSV-2.</p> <p>Data from clinical studies of varicella zoster virus therapeutic vaccines might provide information on potential cell-mediated immunity correlates that might be measurable in clinical studies with HSV therapeutic vaccines.</p> <p>In some HSV-1 studies, CD8<sup>+</sup> T cell responses to specific regions of HSV and exhaustion markers on T cells in blood have been proposed as correlates of severity [66] .</p>

	Gap	Notes
		In most HSV clinical trials, peripheral blood is sampled for cell-mediated immunity, but the most relevant cells might be resident in the mucosal tissue and, therefore, less available for measurement.
	An improved understanding of the neutralizing antibody responses to HSV-1 and -2 is needed, including epitope mapping and analysis of structure-function relationships.	Higher-throughput assays for neutralizing antibodies, and with better specificity, will be required; some of which are being developed [67].
	For use in future trials of prophylactic vaccines, is it possible to develop assays that measure prevention or reduction of future transmission of HSV? These could be used as an alternative to seroconversion and achievement of, so-called, sterilizing immunity.	Serological studies (such as antibody avidity) or measurements of cell-mediated immunity (such as T-cell maturation) might predict risk of HSV transmission and could be used as surrogate endpoints. Measuring the amount of virus shed over a three-month period might be another option.
	<p>A better understanding of the sequence variation between different isolates of HSV from different geographic regions is needed [68] and is being developed [69].</p> <p>The impact of genomic diversity on diagnostics, non-vaccine therapeutics and HSV-vaccine design and use also needs to be studied [7].</p>	This should determine whether HSV vaccine development should focus on proteins that are more conserved between isolates and/or whether different vaccines are needed for different regions.

	Gap	Notes
<b>Regulatory</b>	<p>Which endpoint(s) will national regulatory authorities view as acceptable for licensing HSV prophylactic and therapeutic vaccines?</p> <p>Can effects on HIV be incorporated into the license (and label) for HSV vaccines?</p>	<p>For first-generation HSV vaccines, clinical endpoints such as prevention of infection or GUD (for prophylactic vaccines) and reduction in GUD (therapeutic vaccines) may be most likely to be adopted by regulators</p> <p>If prevention of HIV is to be included as an HSV vaccine indication, HIV endpoints measureable in clinical trials are likely to be required.</p>

730



**Figure 1. Summary of the possible impacts of HSV-2 infection and HSV vaccines on HIV acquisition**

Upon HSV infection of Person B (HSV-2 susceptible partner) from Person A (HSV-2 source partner), initial mucosal replication results in establishment of latency in the dorsal ganglia, with subsequent reactivation episodes. Mucosal replication during initial infection or reactivation can result in HSV-associated genital ulcer disease (in Person B) and HSV transmission, through either asymptomatic or symptomatic HSV-2 shedding (to Person C). The presence of genital ulcers during primary infection or a reactivation episode, and infiltration of (CD4<sup>+</sup>) immune cells responding to either asymptomatic or symptomatic mucosal infection, increase Person B's risk of HIV acquisition (from Person C). Prophylactic HSV vaccination of Person B could prevent HSV infection from Person A or reduce subsequent reactivation on breakthrough infection. Thereby, prophylactic HSV vaccination could reduce genital ulcer disease, HSV shedding, and infiltration of mucosal (CD4<sup>+</sup>) immune cells, which could decrease risk of HIV acquisition. Therapeutic vaccination of Person B after HSV infection could reduce reactivation of HSV, or could reduce genital ulcers and HSV shedding, and alter immune cells in the mucosa directly. Depending on the vaccine's mechanism, it may increase or decrease activated CD4<sup>+</sup> T cells in the genital tract, which could have varying effects on the risk of HIV acquisition.

Currently in development:




Figure 2. Summary of the HSV vaccine pipeline